-
HOBt: Stereochemical Control in Amide Synthesis
2026-09-20
HOBt (1-Hydroxybenzotriazole) is more than a peptide coupling additive: it is a route-control reagent that can improve activated-ester chemistry and protect stereochemical fidelity. This article connects its mechanism to medicinal-chemistry decisions using a glucagon receptor antagonist synthesis as a practical case study.
-
Dexamethasone Workflows for Translational Assays
2026-09-19
Build more interpretable inflammation, differentiation, autophagy, and neurobiology assays with Dexamethasone (DHAP). This guide connects practical dosing and controls with mutation-aware cell-line selection inspired by a large multiple myeloma study.
-
Estradiol Workflows for ER Signaling and Autophagy
2026-09-19
Estradiol workflows can connect receptor-specific transcription, rapid kinase responses, and autophagy to measurable cardiovascular, renal, and cancer-biology phenotypes. This practical guide covers stock handling, dose–time design, mechanistic controls, and troubleshooting for studies using 17 beta-estradiol.
-
RNase R and Circular RNA in Inflammation
2026-09-18
Circular RNAs are increasingly viewed as mechanistic regulators of inflammation rather than passive biomarkers. This thought-leadership article connects the circ_0042103/TAF15/NER axis in pulpitis with a rigorous validation strategy based on selective linear RNA digestion. It explains how Ribonuclease R (RNase R) (20 U/μL) can support circular RNA enrichment, RNA structure analysis, and translational study design while clarifying the limits of RNase R resistance as evidence of circularity.
-
Dyngo-4a: Dynamin Inhibitor Workflow Guide
2026-09-18
Dyngo-4a is a research-grade dynamin inhibitor for dissecting vesicle scission, clathrin-dependent endocytosis, and cargo uptake. This guide translates its mechanism into practical dose-response, serial delivery, imaging, and troubleshooting workflows, including how to compare trafficking perturbation with lipid nanoparticle mRNA engineering.
-
Caffeine: From Mechanism to Translational Strategy
2026-09-17
Caffeine is a tractable adenosine receptor antagonist and metabolic research tool. This thought-leadership article connects its cancer and obesity-model evidence with a target-validation framework inspired by recent ALDH2 activator research, while separating reproducible laboratory evidence from translational hypotheses.
-
B7464 CK2 and ERK8 Inhibitor Research Guide
2026-09-17
B7464 is a small molecule inhibitor chemically identified as 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid. Product documentation supports its use as a research tool for CK2- and ERK8-linked phosphorylation, while the cited SARS-CoV-2 study supports GCG—not B7464—as the compound that disrupted nucleocapsid phase separation.
-
Protease Inhibitor Cocktail EDTA-Free: K1010
2026-09-16
The Protease Inhibitor Cocktail EDTA-Free K1010 is a 100X DMSO concentrate for broad protease control during protein extraction and sample preparation. Its EDTA-free formulation is suited to phosphorylation-sensitive workflows and assays that require divalent cations.
-
WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis
2026-09-15
The reference study identifies the WNT5a/GSK3/β-catenin axis as a major regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors. By combining pharmacological screening, mass cytometry, animal models, network analysis, and transcriptomic datasets, it connects pathway activity with fatty degeneration and FAP support of muscle regeneration.
-
CAF–ANGPTL4-IQGAP1 Chemoresistance in Prostate Cancer
2026-09-15
The reference study identifies a paracrine ANGPTL4–IQGAP1 pathway through which cancer-associated fibroblasts reprogram prostate cancer mitochondrial metabolism and reduce chemotherapy sensitivity. Its integrated proteomic, metabolic, interaction, and pharmacological experiments position IQGAP1 and the CAF secretome as experimentally testable targets, while QGGP provides an initial small-molecule lead for combination strategies.
-
Protease Inhibitor Cocktail EDTA-Free Guide
2026-09-14
This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1007, can protect protein endpoints associated with viability, proliferation, and cytotoxicity experiments. It covers compatibility with phosphorylation analysis, practical dilution and storage decisions, and criteria for selecting a reliable ready-to-use inhibitor formulation.
-
Reactive Oxygen Species Assay Kit for Live Cells
2026-09-14
Translate radiation, nanoparticle, and drug-induced oxidative stress into measurable live-cell fluorescence with a practical DCFH-DA workflow. The assay combines a defined positive control with decision-ready controls for radiosensitization, apoptosis, and cancer research oxidative stress studies.
-
NF 340: Mapping P2Y11 Signaling in Cancer
2026-09-13
Explore how the P2Y11 antagonist NF 340 can help separate receptor-dependent signaling from downstream effects in breast cancer invasion assays. This evidence-led guide translates QPRT–purinergic signaling findings into practical experimental decisions while defining limitations for immunology research.
-
EZH2 Inhibition in Fragile X Syndrome Neurons
2026-09-12
Fang and colleagues identify EZH2 as a functional contributor to FMR1 silencing and show that pharmacological or antisense inhibition can restore FMR1-related molecular and electrophysiological phenotypes in fragile X syndrome neurons. The work provides a mechanistic foundation for EZH2-directed reactivation strategies while highlighting blood–brain barrier penetration and delivery as major translational challenges.
-
Polymyxin B Sulfate: Mechanism and Research Use
2026-09-12
Polymyxin B sulfate is a cationic polypeptide antibiotic used in research on multidrug-resistant Gram-negative bacteria, membrane injury, immune signaling, and bacteremia. Its principal value is rapid membrane disruption, while nephrotoxicity, neurotoxicity, limited activity against many non-target organisms, and assay-specific immune effects define important boundaries.